Grifols, S.A. (NASDAQ:GRFS) Shares Purchased by Creative Planning

Creative Planning increased its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 26.4% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,319 shares of the biotechnology company’s stock after purchasing an additional 3,614 shares during the quarter. Creative Planning’s holdings in Grifols were worth $154,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GRFS. Brandes Investment Partners LP increased its position in Grifols by 8.7% during the 2nd quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock worth $117,242,000 after purchasing an additional 1,481,924 shares in the last quarter. Armistice Capital LLC increased its position in Grifols by 18.7% during the 2nd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock worth $49,759,000 after purchasing an additional 1,244,000 shares in the last quarter. Capital World Investors increased its position in Grifols by 4.9% during the 1st quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company’s stock worth $138,605,000 after purchasing an additional 961,700 shares in the last quarter. Highland Peak Capital LLC acquired a new stake in Grifols during the 2nd quarter worth approximately $5,991,000. Finally, Black Creek Investment Management Inc. boosted its holdings in Grifols by 7.7% in the 2nd quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock worth $77,799,000 after acquiring an additional 881,155 shares during the period.

Analyst Ratings Changes

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Price Performance

Grifols stock opened at $9.32 on Tuesday. The company has a current ratio of 1.68, a quick ratio of 0.80 and a debt-to-equity ratio of 1.06. The stock has a 50 day moving average of $8.85 and a 200-day moving average of $7.93. Grifols, S.A. has a 52 week low of $5.30 and a 52 week high of $12.15.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.